HLA-C and cancer: Interestingly, the two subgroups of the CS3 cluster identified by the cell death landscape not only have distinct survival outcomes but also were correlated with different molecular features—for example, patients in group A had a positive enrichment in CD8 T cell effector, antigen processing and presenting machinery (APM), immune-checkpoint, TME score, INFG signature, MHC classes I and II, ICB resistance, and T cell exhaustion (Figure 6C), whereas group B was much more inclined to cancer hallmark pathways like DDR (Figure 6C).